This data package provides information on inactive ingredients present in FDA-approved drug products as well as dissolution methods presently recommended by the Food and Drug Administration (FDA) for drug products that do not have dissolution test methods in the United States Pharmacopeia (USP). It also includes a fraction of the potentially hazardous products with hidden ingredients marketed to consumers on the internet and in retail establishments.
This data package gives access to FDA inactive ingredients data. For new drug development purposes, once an inactive ingredient has appeared in an approved drug product for a particular route of administration, the inactive ingredient is not considered new and may require a less extensive review the next time it is included in a new drug product. The data package also includes the FDA Drug Dissolution Methods data that FDA is providing to aid industry personnel in developing generic drug products. The data package also enlists potentially hazardous products with hidden ingredients marketed to consumers on the internet and in retail establishments.
License Information
The use of John Snow Labs datasets is free for personal and research purposes. For commercial use please subscribe to the Data Library on AWS. The subscription will allow you to use all John Snow Labs datasets and data packages for commercial purposes.
Metadata
Description
Value
Data Package Complexity
Simple
Available Enrichments
N/A
Keywords
Inactive Ingredients, UNII, FDA Registration, FDA Regulations, Inactive Ingredients, FDA Approval Calendar, FDA Inactive Ingredients, Unique Ingredient Identifier, Dissolution Methods, Dissolution Test Method
Other Titles
FDA Drug Ingredients and Development Process, US Drug Ingredients and Development Process
Included Datasets
Drugs Inactive Ingredients Database
The Inactive Ingredient Database provides information on inactive ingredients present in Food and Drug Administration (FDA) approved drug products. This information can be used by industry as an aid in developing drug products.
FDA Drug Dissolution Methods
For a drug product that does not have a dissolution test method in the United States Pharmacopeia (USP), the Food and Drug Administration (FDA) Dissolution Methods Database provides information on dissolution methods presently recommended by the Division of Bioequivalence, Office of Generic Drugs.
Tainted Products Marketed as Dietary Supplements
The tainted products marketed as dietary supplements dataset includes a small fraction of the potentially hazardous products with hidden ingredients marketed to consumers on the internet and in retail establishments.
Data Engineering Overview
We deliver high-quality data
Each dataset goes through 3 levels of quality review
2 Manual reviews are done by domain experts
Then, an automated set of 60+ validations enforces every datum matches metadata & defined constraints
Data is normalized into one unified type system
All dates, unites, codes, currencies look the same
All null values are normalized to the same value
All dataset and field names are SQL and Hive compliant
Data and Metadata
Data is available in both CSV and Apache Parquet format, optimized for high read performance on distributed Hadoop, Spark & MPP clusters
Metadata is provided in the open Frictionless Data standard, and its every field is normalized & validated
Data Updates
Data updates support replace-on-update: outdated foreign keys are deprecated, not deleted
Our data is curated and enriched by domain experts
Each dataset is manually curated by our team of doctors, pharmacists, public health & medical billing experts:
Field names, descriptions, and normalized values are chosen by people who actually understand their meaning
Healthcare & life science experts add categories, search keywords, descriptions and more to each dataset
Both manual and automated data enrichment supported for clinical codes, providers, drugs, and geo-locations
The data is always kept up to date – even when the source requires manual effort to get updates
Support for data subscribers is provided directly by the domain experts who curated the data sets
Every data source’s license is manually verified to allow for royalty-free commercial use and redistribution.
John Snow Labs, an AI and NLP for healthcare company, provides state-of-the-art software, models, and data to help healthcare and life science organizations build, deploy, and operate AI projects.
AWS Marketplace now accepts line of credit payments through the PNC Vendor Finance program. This program is available to select AWS customers in the US, excluding NV, NC, ND, TN, & VT.
This listing uses a single pricing dimension. Product Access (Units) grants you access to the product as a subscriber at no cost. There are no tiers, instance sizes, or usage add-ons to choose between. You subscribe once to gain access, and billing stays flat with no scaling charges. This structure gives you a straightforward, free entry point with no quantity decisions to make.
Top-of-mind questions for buyers
What does one unit of Product Access grant me?
One unit of Product Access grants you subscriber access to the Drug Ingredients and Development Process product. It is a single access grant, not tied to servers, seats, or usage volume. You subscribe once, and the unit covers your access at no cost.
Does my cost change as my usage or data volume grows?
No. This listing has one flat, free access dimension with no usage meters or tiers. Your cost does not change when you process more documents, add users, or scale workloads. There are no thresholds, overage charges, or automatic upgrades to trigger a bill change.
What healthcare capabilities does this product cover?
The product addresses drug ingredients and development process data as part of the vendor's healthcare AI stack. This includes extracting and structuring clinical and life-sciences information from text. It is built for healthcare use and runs inside your own environment.
Tell us how we can improve this page, or report an issue with this product.
Give us feedbackReport a problem with this product or seller
Legal
Vendor terms and conditions
Upon subscribing to this product, you must acknowledge and agree to the terms and conditions outlined in the vendor's End User License Agreement (EULA).
Content disclaimer
Vendors are responsible for their product descriptions and other product content. AWS does not warrant that vendors' product descriptions or other product content are accurate, complete, reliable, current, or error-free.
SG4D100M is a state-of-the-art molecular foundation model that revolutionizes drug discovery and chemical development. Built on advanced transformer architecture with SE(3) invariance, it enables accurate molecular property prediction and structural analysis across pharmaceutical, specialty chemical, and agricultural applications.
The cabergoline market involves the global production and distribution of a potent dopamine agonist used primarily to treat hyperprolactinemia and pituitary tumors while also serving as an adjunctive therapy for Parkinsons disease. Driven by a rising prevalence of endocrine disorders and the widespread availability of cost effective generic versions the market is characterized by consistent clinical adoption and high patient adherence. Pharmaceutical manufacturers are focusing on high potency production standards and expanded access in emerging markets to meet the growing demand for effective long term hormonal and neurological management solutions.
The global shellac market anticipates steady expansion, driven by rising demand for natural, eco-friendly materials in food, pharmaceuticals, cosmetics, and wood coatings. Valued at USD 200.0 million in 2024, projections estimate the market reaching USD 240.0 million by 2030, with a CAGR of 4.82% from 2025 onward. This report examines key growth drivers, challenges, market segments, regional dynamics, and strategic advancements shaping the industry trajectory.